期刊文献+

羟丙基-β-环糊精对兰索拉唑的增溶作用及其包合物的制备 被引量:7

Solubilization of lansoprazole using hydroxypropyl-β-cyclodextrin and preparation of their inclusion complexes
下载PDF
导出
摘要 目的研究羟丙基-β-环糊精(HP--βCD)对难溶性药物兰索拉唑(LPZ)的包合作用。方法绘制相溶解度图,考察pH变化、碳酸氢钠的加入对LPZ的增溶作用。采用共蒸发法(CE)和喷雾干燥法(SD)按照LPZ∶HP--βCD量比为1∶1或1.0∶1.5的比例制备LPZ/HP--βCD包合物,测定其溶出度,并利用差示扫描量热法(DSC)和傅立叶红外光谱法(FTIR)对SD法制备的包合物进行结构表征。结果在pH 11条件下,HP-β-CD与NaHCO3对LPZ的协同增溶效果最好。体外溶出实验表明:CE法和SD法制备的包合物溶出均优于LPZ与HP-β-CD的物理混合物。结论HP--βCD能明显提高LPZ的溶解度和溶出度。 Objective To investigate the complexation of lansoprazole (LPZ) with hydroxylpropyl-β-cyclo- dextrin( HP-β-CD). Methods The phase solubility diagrams of LPZ versus HP-β-CD were plotted for analy- sing the influence of buffer pH and the presence of NaHCO3 on HP-β-CD complexation of LPZ. Solid inclu- sion complexes of LPZ/HP-β-CD were prepared in 1: 1 or 1.0:1.5 mole ratios with the addition of NaHCO3 by the co-evaporating method(CE) and spray drying method( SD), the characteristics of which were studied preliminarily by in vitro dissolution test, differential scanning calorimetry (DSC)and fourier transform infrared(FTIR) spectroscopy. Results Total drug solubility was evidently enhanced under pH 11 by combined using HP-β-CD and NaHCO3. In vitro study, the complexes prepared by CE or SD both enhanced the dissolution rate and accumulate dissolution of LPZ in pH 6.8 buffer solution comparing with LPZ and the physical mixture of LPZ and HP-β-CD. Conclusions The solubility and dissolution rate of LPZ are improved by HP-β-CD complexation obviously.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2009年第3期165-169,175,共6页 Journal of Shenyang Pharmaceutical University
关键词 兰索拉唑 羟丙基-Β-环糊精 包合物 溶出度 lansoprazole HP-β-CD inclusion complexes dissolution
  • 相关文献

参考文献9

  • 1BARRADELL L B, FAULDS D, MCTAVISH D. Lansoprazole, a review of its pharmacodynamic and pharmacokinetics properties and its therapeutic efficacy in acid-related disorders [ J ]. Drugs, 1992,44:225 - 250.
  • 2YUKAKO I, HARUMI A, KAORI U, et al. Effect of adsorbents on the absorption of lansoprazole with surfactant [ J ]. International Journal of Pharmaceutics, 2005,289: 69 - 77.
  • 3AMIDON GL,LENNERNAS H,SHAH V P,et al. A theoretical basis for a biopharmaceutic drug classifycation:the correlationof in vitro drug product dissolution and in vivo bioavailability [ J ]. Pharm Res, 1995,12, 413 -420.
  • 4丁平田,吴雪梅.药物制剂的新型辅料2-羟丙基-β-环糊精[J].国外医药(合成药.生化药.制剂分册),1996,17(2):107-111. 被引量:62
  • 5HIGUCHI T, CONNORS K. Phase-solubility teclmiques[ J]. Adv Anal Ctwm Lnstrum, 1965,4: 117 - 212.
  • 6杨艳,谢俊霞,李冰,孙英华,方金玲,刘艳,何仲贵.HPLC测定注射用兰索拉唑中兰索拉唑的含量和有关物质[J].中国药学杂志,2006,41(7):538-540. 被引量:22
  • 7MAKINO T,TABATA T,HIRAI S. Stabilized pharmaceutical composition comprising a benzimidazole compound,its production and its use as an antiulcer agent: European Patent,0237200A2 [ P], 1982 - 02 - 13.
  • 8REDENTI E, SZENTE L, SZEJTLI J. Cyclodextrin complexes of salts of acidic drugs. Thermo-dynamic properties, structural features, and pharmaceutical applications[J]. J Pharm Sci,2001,90(8) :979 -986.
  • 9CIRRI M, MAESTRELLI F, CORTI G, et al. Simultaneous effect of cyclodextrin complexation, pH, and hydro-philic polymers on naproxen solubilization [ J ]. Journal of Pharmaceutical and Biomedical Analysis, 2006,42 : 126 - 131.

二级参考文献5

  • 1KAROL M D,GRANNEMAN G R,ALEXANDER K.Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography[J].J Chromatography B,668(1995):182-186.
  • 2中国药典 2000 年版.二部[S].2000.
  • 3ALBIN K,FRANC V.Preformulation investigation of the novel proton pump inhibitor lansoprazole[J].Drug Development and Industrial Pharmacy,26(7):781-783(2000).
  • 4林斌.反相HPLC法测定兰索拉唑原料及片剂的含量[J].广东药学院学报,1998,14(4):247-249. 被引量:7
  • 5杨应霓,余海宣,李庆南,罗梓河.兰索拉唑及其片剂的稳定性研究[J].中国现代应用药学,2003,20(3):203-205. 被引量:9

共引文献82

同被引文献62

引证文献7

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部